ENAapplication/xmlprimaryOK2000000GenomicsNHLBIhttps://www.ebi.ac.uk/ena/browser/view/PRJNA414680Homo sapiensECLIPSE was a longitudinal observational study of 2164 COPD subjects and a smaller number of smoking controls (337) and nonsmoking controls (245) followed regularly for three years, with three chest CT scans (at baseline, one year, and three years) (Vestbo et al., 2008, PMID: 18216052). Subjects were enrolled at clinical centers in the US, Canada, Europe, and New Zealand. Inclusion criteria included subjects ages 40-75, at least 10 pack-years of smoking, and spirometry in GOLD grades 2-4 (COPD cases) or normal spirometry with post-bronchodilator FEV1 >85% (predicted) and FEV1/FVC>0.7 (controls). Study visits were performed at enrollment, three months, and every six months thereafter with spirometry, questionnaires, and other clinical evaluations. The ECLIPSE CT scans have been... (for more see dbGaP study page.)ENAViral Marker, Biological Markers, Surrogate Endpoints, Clinical Markers, Laboratory, DISEASE (COPD), Clinical Marker, Chronic Airflow Obstructions, CAO - Chronic airflow obstruction, Biochemical, Endpoint, chronic obstructive pulmonary disease (COPD), CHRONIC OBSTRUCTIVE PULM DIS, Chronic obstructive pulmonary disease NOS, Serum, Surrogate End Points, Chronic obstructive pulmonary disease finding, Surrogate Markers, Laboratory Markers, PULMONARY DISEASE (COPD), Pulmonary Disease, Biological, chronic obstructive airways disease NOS (disorder), Chronic irreversible airway obstruction, Chronic Obstructive Pulmonary Disease (COPD), Biomarker, COLD (chronic obstructive lung disease), Clinical, NEC in ICD9CM_2006, Biological Marker, CAFL - Chronic airflow limitation, Chronic Obstructive, Chronic airflow limitation, Immunologic Markers, Immune, Markers, disease (COPD), Viral Markers, NEC, Chronic, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, Immunologic Marker, Biologic, COPD, CHRONIC, COAD - Chronic obstructive airways disease, chronic obstructive lung disease [Ambiguous], obstructive lung disease, Viral, Surrogate Endpoint, chronic obstructive airways disease NOS, Immune Markers., not elsewhere classified, COAD, Serum Markers, End Point, Biochemical Markers, COLD - Chronic obstructive lung disease, Biologic Marker, chronic, PULM DIS CHRONIC OBSTRUCTIVE, Airflow Obstructions, Chronic obstructive pulmonary disease finding (finding), Immune Marker, CHRONIC OBSTRUCTIVE AIRWAY DIS, pulmonary disease (COPD), Marker, Surrogate End Point, CHRONIC OBSTRUCTIVE, chronic obstructive pulmonary disease and allied conditions, Chronic airway disease, NOS, (COPD), chronic airway obstruction, Airflow Obstruction, chronic obstructive, CAL - Chronic airflow limitation, COPD NOS, Biologic Markers, CHRONIC OBSTRUCTIVE LUNG DIS, chronic obstructive airway disease, Chronic Obstructive Airways Disease, Chronic airway obstruction, Chronic obstructive lung disease, Serum Marker, End Points, cold, Surrogate, Dops, Endpoints, Immunologic, Laboratory Marker, Surrogate Marker, Chronic Airflow Obstruction, OBSTRUCTIVE PULMONARY DISEASE (COPD), Biochemical Marker, COPD - Chronic obstructive pulmonary disease, chronic obstructive lung disease (disorder), chronic obstructive airways disease, cold (chronic obstructive lung disease), Chronic Obstructive Lung Disease, obstructive pulmonary disease (COPD), COLD, chronic obstructive lung disease, chronic obstructive pulmonary diseaseViral Marker, Biological Markers, Surrogate Endpoints, Clinical Markers, Laboratory, DISEASE (COPD), Clinical Marker, Chronic Airflow Obstructions, CAO - Chronic airflow obstruction, Biochemical, Endpoint, chronic obstructive pulmonary disease (COPD), CHRONIC OBSTRUCTIVE PULM DIS, Chronic obstructive pulmonary disease NOS, Serum, Surrogate End Points, Chronic obstructive pulmonary disease finding, Surrogate Markers, Laboratory Markers, PULMONARY DISEASE (COPD), Pulmonary Disease, Biological, chronic obstructive airways disease NOS (disorder), Chronic irreversible airway obstruction, Chronic Obstructive Pulmonary Disease (COPD), Biomarker, COLD (chronic obstructive lung disease), Clinical, NEC in ICD9CM_2006, Biological Marker, CAFL - Chronic airflow limitation, Chronic Obstructive, Chronic airflow limitation, Immunologic Markers, Immune, Markers, disease (COPD), Viral Markers, NEC, Chronic, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, Immunologic Marker, Biologic, COPD, CHRONIC, COAD - Chronic obstructive airways disease, chronic obstructive lung disease [Ambiguous], obstructive lung disease, Viral, Surrogate Endpoint, chronic obstructive airways disease NOS, Immune Markers., not elsewhere classified, COAD, Serum Markers, End Point, Biochemical Markers, COLD - Chronic obstructive lung disease, Biologic Marker, chronic, PULM DIS CHRONIC OBSTRUCTIVE, Airflow Obstructions, Chronic obstructive pulmonary disease finding (finding), Immune Marker, CHRONIC OBSTRUCTIVE AIRWAY DIS, pulmonary disease (COPD), Marker, Surrogate End Point, CHRONIC OBSTRUCTIVE, chronic obstructive pulmonary disease and allied conditions, Chronic airway disease, NOS, (COPD), chronic airway obstruction, Airflow Obstruction, chronic obstructive, CAL - Chronic airflow limitation, COPD NOS, Biologic Markers, CHRONIC OBSTRUCTIVE LUNG DIS, chronic obstructive airway disease, Chronic Obstructive Airways Disease, Chronic airway obstruction, Chronic obstructive lung disease, Serum Marker, End Points, cold, Surrogate, Dops, Endpoints, Immunologic, Laboratory Marker, Surrogate Marker, Chronic Airflow Obstruction, OBSTRUCTIVE PULMONARY DISEASE (COPD), Biochemical Marker, COPD - Chronic obstructive pulmonary disease, chronic obstructive lung disease (disorder), chronic obstructive airways disease, cold (chronic obstructive lung disease), Chronic Obstructive Lung Disease, obstructive pulmonary disease (COPD), COLD, chronic obstructive lung disease, chronic obstructive pulmonary disease0.00.00.00.00.00falseNHLBI TOPMed: Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)NHLBI TOPMed: Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)2022-06-052017-10-20PRJNA4146809606